Of all the changes the ongoing coronavirus pandemic forced on us, the change in healthcare has got to be one of the most profound.
Whether we’re managing a chronic condition, like high blood pressure, say, or an acute illness like strep throat, the market demand for healthcare needs hasn’t decreased a bit, but COVID-19 has made getting in to see a primary or specialist physician a lot more complicated and, in some cases, a lot riskier.
That means telemedicine, and the broader field of digital healthcare, are the name of the game right now. The $20 billion Teledoc-Livongo merger is proof of that.
The best minds in biotech are working round the clock on putting a stop to the COVID-19 pandemic. The project includes over 135 vaccine candidates and the profit potential here is massive.
This is literally about saving the world.
The thing is, though, vaccines are only one part of this project. There’s another dimension, a “silent partner” in the project that doesn’t get quite so much heroic headline ink but is just as important.
You see, of all the vaccines coming down the pipeline, 31 are currently in human trials. There’s a very good chance that one of them will be safe and powerful enough to begin mass distribution in early 2021.
But there are 328 million living Americans and 7.5 billion humans on planet earth. It will take time to vaccinate them all, and that’s where our “silent partner” comes in.
It’s blazing a trail towards the kind of better COVID-19 testing technology we will need to get things fully back to normal.
Looking for a parking spot for 15 minutes, spending 20 minutes filling out forms, and waiting for 30 minutes or more to see your doctor is a relic of the past thanks to virtual medical appointments through our computers and phones.
And it’s easy to see why.
What’s referred to as “telemedicine” can save patients nearly two hours of their time, according to Forbes.
Being in the comfort of their own homes is also a major selling point, as a Doctor.com survey found that 91% of the respondents said telemedicine would:
Help them stick to their appointments.
Manage prescriptions and refills.
Follow wellness regimens suggested by their doctor.
Keep in mind folks that telemedicine was becoming more commonplace, and then COVID-19 sent it into overdrive.
As far as hard numbers go, telemedicine forecasts B.C. (before coronavirus) show this market is only getting more valuable, climbing 127% from $35.5 billion dollars to $80.6 billion by 2025.
So those estimates could be too conservative, and I don’t want you to wait around to make money as this market gets bigger and bigger.
The good news is there’s a fire sale going on in the telemedicine market that we can take advantage of right now that will pave your road to wealth.
I’m talking about Teledoc Health Inc. (TDOC), which got slammed on August 5, closing down 19%.
The reason was that the firm is making a big buyout, one that I think is very savvy.
The COVID-19 pandemic is and has been an unprecedented event, but there’s also something else to think about.
During this moment in history, we have never had a unified global effort quite like this to find an effective vaccine, and the convergence of technology and medicine that we have access to is allowing researchers to work on a vaccine at break-neck speed.
As of this writing, there are currently 28 COVID-19 vaccines in human trials, and the Trump Administration believes it will have an effective vaccine by 2021.
From scientists to business leaders, there’s one thing most people can agree on – life will not return to normal and our economy will not reach maximum production until a vaccine for COVID-19 is in hand. To find this vaccine, the convergence between tech and medicine is creating a biotechnology revolution.
Operation Warp Speed (OWS), an initiative in the United States, aims to deliver over 300 million doses of a safe, effective vaccine for COVID-19 by January 19, 2021.
And as of this writing, what we call a new, viable “Super Vaccine” is pushing to begin production of up to one billion doses. Right now, a tiny company behind the Super-Vaccine has a mere $60 million a year in sales.